Ono Pharmaceutical Co (TSE:4528) Beneish M-Score: -2.69 (As of Jul. 12, 2026)


TSE:4528 Ono Pharmaceutical Co Ltd TSE:4528
89 GF Score
Price 円2,428.00
GF Value 円2,240.58
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Ono Pharmaceutical Co Beneish M-Score?

Ono Pharmaceutical Co TSE:4528 -0.86% 89 Beneish M-Score is -2.69 as of Jul. 12, 2026. GuruFocus rates TSE:4528 with a GF Score™ of 89/100 and a GF Value™ of 円2,240.58 (Fairly Valued). The stock has 4 warning signs investors should review. Among 911 Drug Manufacturers companies, Ono Pharmaceutical Co ranks better than 67.51% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.69 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Ono Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

TSE:4528' s Beneish M-Score Range Over the Past 10 Years
Min: -2.97   Med: -2.54   Max: -2.06
Current: -2.69

During the past 13 years, the highest Beneish M-Score of Ono Pharmaceutical Co was -2.06. The lowest was -2.97. And the median was -2.54.


Ono Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Ono Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ono Pharmaceutical Co Beneish M-Score Chart

Ono Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.16 -2.73 -2.21 -2.97 -2.69

Ono Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.97 -2.75 -2.69 -2.76 -2.69

TSE:4528 vs LLY, JNJ, ABBV: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ono Pharmaceutical Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ono Pharmaceutical Co's Beneish M-Score falls into.


TSE:4528
89GF Score
Ono Pharmaceutical Co Ltd TSE:4528
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ono Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ono Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0202+0.528 * 0.9598+0.404 * 1.0258+0.892 * 1.0594+0.115 * 0.7476
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9291+4.679 * -0.060599-0.327 * 0.904
=-2.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was 円145,936 Mil.
Revenue was 118749 + 139900 + 129600 + 127536 = 円515,785 Mil.
Gross Profit was 85690 + 103219 + 94637 + 90523 = 円374,069 Mil.
Total Current Assets was 円468,308 Mil.
Total Assets was 円1,106,515 Mil.
Property, Plant and Equipment(Net PPE) was 円101,419 Mil.
Depreciation, Depletion and Amortization(DDA) was 円37,752 Mil.
Selling, General, & Admin. Expense(SGA) was 円123,691 Mil.
Total Current Liabilities was 円163,645 Mil.
Long-Term Debt & Capital Lease Obligation was 円82,468 Mil.
Net Income was 818 + 28860 + 22416 + 17673 = 円69,767 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = 円0 Mil.
Cash Flow from Operations was 50182 + 32075 + 51191 + 3373 = 円136,821 Mil.
Total Receivables was 円135,022 Mil.
Revenue was 112309 + 134223 + 122664 + 117675 = 円486,871 Mil.
Gross Profit was 67072 + 95479 + 88366 + 88004 = 円338,921 Mil.
Total Current Assets was 円455,104 Mil.
Total Assets was 円1,064,046 Mil.
Property, Plant and Equipment(Net PPE) was 円105,721 Mil.
Depreciation, Depletion and Amortization(DDA) was 円26,894 Mil.
Selling, General, & Admin. Expense(SGA) was 円125,671 Mil.
Total Current Liabilities was 円148,296 Mil.
Long-Term Debt & Capital Lease Obligation was 円113,500 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(145936 / 515785) / (135022 / 486871)
=0.28294 / 0.277326
=1.0202

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(338921 / 486871) / (374069 / 515785)
=0.696121 / 0.725242
=0.9598

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (468308 + 101419) / 1106515) / (1 - (455104 + 105721) / 1064046)
=0.485116 / 0.472932
=1.0258

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=515785 / 486871
=1.0594

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(26894 / (26894 + 105721)) / (37752 / (37752 + 101419))
=0.202798 / 0.271263
=0.7476

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(123691 / 515785) / (125671 / 486871)
=0.239811 / 0.25812
=0.9291

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((82468 + 163645) / 1106515) / ((113500 + 148296) / 1064046)
=0.222422 / 0.246038
=0.904

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(69767 - 0 - 136821) / 1106515
=-0.060599

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ono Pharmaceutical Co has a M-score of -2.69 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.69 mean?
Ono Pharmaceutical Co (TSE:4528) has a Beneish M-Score of -2.69 as of Jul. 12, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ono Pharmaceutical Co and its competitors. According to the industry distribution chart, Ono Pharmaceutical Co ranks #296 out of 911 companies in the Drug Manufacturers industry, placing it in the top 32.5%.
Is Ono Pharmaceutical Co's Beneish M-Score too high?
Ono Pharmaceutical Co's current Beneish M-Score is -2.69. Based on the distribution chart, Ono Pharmaceutical Co ranks #296 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ono Pharmaceutical Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's Beneish M-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Ono Pharmaceutical Co ranks #296 out of 911 companies for Beneish M-Score. This puts Ono Pharmaceutical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ono Pharmaceutical Co and its competitors. Ono Pharmaceutical Co's current Beneish M-Score is -2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (TSE:4528) is currently considered Fairly Valued. The stock's GF Value™ is 円2,240.58, compared to a current price of 円2,428.00 — trading 8.4% above its estimated fair value. The current Beneish M-Score is -2.69. Ono Pharmaceutical Co's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Ono Pharmaceutical Co (TSE:4528), the current Beneish M-Score is -2.69 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ono Pharmaceutical Co (TSE:4528) Overvalued in 2026?

Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued. The current stock price of 円2,428.00 is trading 8.4% above its estimated GF Value™ of 円2,240.58. GuruFocus considers Ono Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4528:

  • Beneish M-Score: -2.69
  • GF Value™: 円2,240.58 vs. price of 円2,428.00 (8.4% above fair value)
  • GF Score™: 89/100 with 4 warning signs

No single metric tells the full story. See the TSE:4528 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ono Pharmaceutical Co Business Description

Other Exchanges OPHLY:USAON4:Germany
Address 1-8-2 Kyutarocho, Chuo-ku, Osaka, JPN, 541-8564
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
89GF Score

Get the complete analysis for TSE:4528

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,428.00
Price
円2,240.58
GF Value